DelveInsight’s “PCSK9 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034” report delivers an in-depth understanding of PCSK9 inhibitors, historical and competitive landscape, as well as the PCSK9-targeted therapies market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover Key Insights into the PCSK9 Inhibitors Market with DelveInsight’s In-Depth Report @ PCSK9-Targeted Therapies Market Size

Key Takeaways from the PCSK9 Inhibitors Market Report

• The PCSK9-targeted therapies market across the 7MM reached roughly USD 2,413 million in 2024, with the United States alone contributing the largest share at close to USD 1,766 million, and continued expansion is anticipated through 2034.

• The leading PCSK9-targeted therapies companies include Merck Sharp & Dohme, LIB Therapeutics, AstraZeneca, and Eli Lilly (in partnership with Verve Therapeutics), among others.

• Within the 7MM, familial hypercholesterolemia represents a substantial treatment-eligible population, with roughly 336,000 HeFH cases and just over 1,000 HoFH cases identified, alongside a much larger pool of patients eligible based on prior cardiovascular events such as heart attack, stroke, and peripheral artery disease.

• In the United States, cardiovascular event burden remains high, with about 1.3 million acute coronary syndrome cases and over 825,000 stroke cases recorded annually, underscoring the scale of the eligible treatment population.

• EU4 and the UK carry the largest treatment-eligible pool tied to secondary-prevention ASCVD patients, spanning peripheral arterial disease, acute coronary syndrome, and stroke history.

• The pipeline is moving decisively toward more convenient, less invasive modalities, with oral agents and one-time gene-editing approaches positioned to reshape the competitive landscape over the next decade.

Stay ahead in the PCSK9 Inhibitors Market with DelveInsight’s Strategic Report @ PCSK9-Targeted Therapies Market Outlook

PCSK9-Targeted Therapies Epidemiology Segmentation in the 7MM

• Total Cases of Selected Indications for PCSK9 Inhibitors

• Total Eligible Patient Pool for PCSK9 Inhibitors in Selected Indications

• Total Treated Cases in Selected Indications for PCSK9 Inhibitors

• Familial Hypercholesterolemia (HeFH and HoFH) Diagnosed Prevalent Cases

• ASCVD Secondary-Prevention Treatment-Eligible Cases (Prior MI, Stroke, PAD)

PCSK9-Targeted Therapies Pipeline Analysis

Enlicitide Decanoate: Merck Sharp & Dohme

An investigational oral macrocyclic peptide designed to be the first pill-based PCSK9-targeted therapy, working through the same LDL-C-lowering mechanism as injectable monoclonal antibodies. It was recognized by the drug discovery community as a standout molecule in 2023, and in June 2025 Merck reported positive top-line results from the first two pivotal Phase III trials evaluating the drug in adults with hyperlipidemia.

Lerodalcibep (LIB-003): LIB Therapeutics

A third-generation PCSK9-targeted therapy engineered as a low-volume, once-monthly subcutaneous injection with long shelf stability, aimed at overcoming the dosing burden of existing options. The FDA accepted the company’s filing in February 2025, and by December 2025 the therapy — now marketed as Lerochol — received FDA approval for ASCVD and HeFH patients, followed by a February 2026 approval covering the broader population of adults with elevated LDL-C. Clinical trials showed reductions in LDL-C exceeding 60%.

Laroprovstat (AZD0780): AstraZeneca

An oral small-molecule candidate in development alongside Merck’s enlicitide as part of the push toward pill-based PCSK9 inhibition. The drug posted positive results in the Phase IIb PURSUIT trial reported in March 2025.

VERVE-102: Eli Lilly / Verve Therapeutics

A one-time in vivo gene-editing therapy designed to permanently silence the PCSK9 gene in the liver. Data reported in May 2026 showed a single dose reduced circulating PCSK9 protein by as much as 88% and LDL-C by up to 62%, with the effect remaining durable over extended follow-up — positioning it as a potential curative, disruptive alternative to chronic dosing.

STX-1150: Scribe Therapeutics

A CRISPR-based epigenetic silencing candidate that turns down PCSK9 gene expression without cutting DNA, intended to deliver durable LDL-C reduction from a single administration. The company expects the therapy to enter clinical trials in mid-2026.

Rona Therapeutics’ bi-valent siRNA

A dual-target siRNA candidate now in clinical development that addresses both PCSK9 and Lipoprotein(a) simultaneously, notable as the first therapy of its kind aimed at Lp(a), a genetic cardiovascular risk factor that currently lacks any approved targeted treatment.

PCSK9-Targeted Therapies Market Insights

Currently marketed options are dominated by monoclonal antibodies REPATHA (evolocumab, Amgen) and PRALUENT (alirocumab, Sanofi/Regeneron), which deliver substantial LDL-C reduction but require frequent injections and face real-world access constraints. LEQVIO (inclisiran, Novartis/Alnylam), a twice-yearly siRNA therapy, offers a more convenient dosing schedule and is expected to see continued adoption growth, particularly after its label expansion for statin-intolerant patients.

Sales of REPATHA and PRALUENT are expected to soften over the forecast period as newer entrants — including oral candidates and the recently approved Lerochol — draw share, reflecting a broader shift toward therapies that ease the adherence burden associated with regular injections.

A pipeline spanning oral small molecules, gene editing, and dual-target siRNA approaches is expected to substantially expand the overall market opportunity, with oral PCSK9 therapies alone projected to potentially expand total market size two- to three-fold once launched.

Get In-Depth Knowledge on PCSK9 Inhibitors Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/report-store/pcsk9-inhibitors-market

PCSK9 Inhibitors Market Outlook

PCSK9-targeted therapies work by blocking a liver protein that would otherwise degrade LDL receptors, preserving the liver’s ability to clear LDL cholesterol from the bloodstream and delivering reductions of roughly 50–60%. Beyond lipid lowering, these therapies meaningfully cut the risk of heart attack, stroke, and other cardiovascular events, making them a cornerstone option for both primary and secondary prevention, typically used alongside statins or as an alternative for statin-intolerant patients.

The competitive landscape is shifting quickly. Injectable monoclonal antibodies still dominate today, but siRNA-based LEQVIO is expected to become a blockbuster, while oral agents from Merck and AstraZeneca — and eventually one-time gene-editing treatments from Verve — are poised to redefine the category by removing the adherence barriers tied to regular injections. The United States is expected to remain the largest and fastest-growing market given more permissive access, while EU4 and the UK growth will lean on structured reimbursement pathways, and Japan’s uptake is expected to accelerate as oral options become available given a strong regional preference for non-injectable treatment.

Scope of the PCSK9 Inhibitors Market Report

• Coverage: 7MM

• Study Period: 2020–2034

• Forecast Period: 2024–2034

• PCSK9-Targeted Therapies Companies: Merck Sharp & Dohme, LIB Therapeutics, AstraZeneca, Eli Lilly (Verve Therapeutics), and others

• PCSK9-Targeted Therapies: REPATHA, PRALUENT, LEQVIO, Enlicitide decanoate, Lerodalcibep (Lerochol), Laroprovstat, VERVE-102, and others

• PCSK9 Inhibitors Market Access & Reimbursement, Unmet Needs and Perspectives

• PCSK9 Inhibitors SWOT Analysis and KOL Views

Unlock Strategic Insights with DelveInsight’s Comprehensive PCSK9 Inhibitors Market Report @ PCSK9-Targeted Therapies Market Drivers and Barriers

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. PCSK9-targeted Therapies Market Overview at a Glance

7. Background and Overview

8. Introduction

9. Epidemiology and Patient Population

10. Marketed Drugs

11. Emerging Drugs

12. PCSK9-targeted Therapies: The Seven Major Market Analysis

13. Unmet Needs

14. SWOT Analysis

15. KOL Views

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Related Reports

PCSK9 Inhibitors Epidemiology Forecast – 2034

DelveInsight’s ‘PCSK9 Inhibitors (PCSK9i) disease – Epidemiology Forecast to 2034’ report delivers an in-depth understanding of PCSK9i, historical and forecasted epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom),and Japan.

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/pcsk9-inhibitors-market